C.R. Bard’s (BCR) Hold Rating Reaffirmed at Jefferies Group LLC

C.R. Bard, Inc. (NYSE:BCR)‘s stock had its “hold” rating reiterated by equities researchers at Jefferies Group LLC in a report issued on Thursday. They presently have a $317.00 price target on the medical instruments supplier’s stock. Jefferies Group LLC’s price target suggests a potential downside of 1.03% from the company’s previous close.

Several other equities research analysts have also recently weighed in on BCR. BidaskClub cut C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a report on Tuesday, June 20th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. C.R. Bard has an average rating of “Hold” and a consensus target price of $285.67.

Shares of C.R. Bard (NYSE BCR) traded up 0.17% during midday trading on Thursday, reaching $320.85. The company’s stock had a trading volume of 246,479 shares. The company has a market capitalization of $23.32 billion, a P/E ratio of 42.12 and a beta of 0.60. The company’s 50-day moving average price is $320.28 and its 200 day moving average price is $296.54. C.R. Bard has a 12-month low of $203.63 and a 12-month high of $324.58.

C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. C.R. Bard’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.54 EPS. On average, equities research analysts forecast that C.R. Bard will post $11.84 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “C.R. Bard’s (BCR) Hold Rating Reaffirmed at Jefferies Group LLC” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://stocknewstimes.com/2017/09/14/c-r-bards-bcr-hold-rating-reaffirmed-at-jefferies-group-llc.html.

In other news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.80% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Toronto Dominion Bank raised its position in shares of C.R. Bard by 26.1% in the 2nd quarter. Toronto Dominion Bank now owns 24,528 shares of the medical instruments supplier’s stock worth $7,752,000 after acquiring an additional 5,077 shares in the last quarter. Banco BTG Pactual S.A. bought a new position in shares of C.R. Bard in the 2nd quarter worth approximately $7,271,000. WINTON GROUP Ltd bought a new position in shares of C.R. Bard in the 2nd quarter worth approximately $3,947,000. Nomura Holdings Inc. raised its position in shares of C.R. Bard by 2,381.1% in the 2nd quarter. Nomura Holdings Inc. now owns 288,572 shares of the medical instruments supplier’s stock worth $91,272,000 after acquiring an additional 276,941 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of C.R. Bard by 6,475.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 789 shares of the medical instruments supplier’s stock worth $249,000 after acquiring an additional 777 shares in the last quarter. 79.34% of the stock is owned by hedge funds and other institutional investors.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply